Related Experiment Video

Updated: Jan 26, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

370

Integrating Osimertinib in Clinical Practice for Non-Small Cell Lung Cancer Treatment

Senthil Rajappa1, M Vamshi Krishna2, Prasad Narayanan3

  • 1Medical Oncologist, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, 500034, India. senthiljrajappa@gmail.com.

Advances in Therapy
|April 4, 2019
PubMed

Insights

Osimertinib offers survival benefits as a first-line treatment for non-small cell lung cancer (NSCLC) with EGFR mutations, overcoming resistance and CNS relapse concerns. This advances precision medicine for advanced NSCLC patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Precision Medicine

Background:

  • First- and second-generation EGFR TKIs were standard for EGFR-mutated NSCLC but resistance, often via T790M mutation, and CNS relapse are issues.
  • Third-generation EGFR-TKI osimertinib shows promise, initially for T790M-mutant NSCLC, and now demonstrates survival benefits in TKI-naïve patients, including those with CNS metastasis.

Purpose of the Study:

  • To evaluate the efficacy and safety of first-line osimertinib compared to standard EGFR TKIs in patients with advanced NSCLC harboring EGFR mutations.
  • To assess the impact of osimertinib on progression-free survival, overall survival, and quality of life, particularly in patients with central nervous system metastases.

Main Methods:

  • The FLAURA study, a randomized, double-blind, phase III trial, compared first-line osimertinib against standard EGFR TKIs (gefitinib or erlotinib) in TKI-naïve patients with advanced EGFR-mutated NSCLC.
  • Key endpoints included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and safety profile.

Main Results:

  • Osimertinib demonstrated a statistically significant PFS benefit and prolonged all post-progression outcomes compared to standard TKIs.
  • The FLAURA study showed improved survival outcomes, including in patients with CNS metastases, with acceptable toxicity and better quality of life.
  • Osimertinib's efficacy in the first-line setting is particularly relevant where T790M testing is not routine, allowing pragmatic use.

Conclusions:

  • First-line osimertinib is favored for patients with advanced EGFR-mutated NSCLC, offering survival advantages and addressing resistance mechanisms and CNS relapse.
  • These findings support osimertinib as a new standard of care in the first-line treatment of EGFR-mutated NSCLC, simplifying treatment sequencing.
  • Further mature overall survival data will be crucial for defining optimal personalized treatment strategies for advanced NSCLC.
Keywords:
Epidermal growth factor receptor tyrosine kinase inhibitorsFirst-lineNon-small cell lung cancerOsimertinibT790M

More Related Videos

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.1K
Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

7.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.2K
Characteristics of Practical Op Amps01:16

Characteristics of Practical Op Amps

A difference amplifier, a crucial component in numerous electronic devices, ideally amplifies only the difference-mode signal, which is the difference between two input signals. However, in practical circuits, the output voltage depends on both the differential gain and the common-mode gain.
The ratio of differential gain to the common-mode gain is defined as the common-mode rejection ratio (CMRR). This ratio quantifies the ability of operational amplifiers (op-amps) to reject common-mode...
843
Theoretical Foundations of Nursing Practice01:30

Theoretical Foundations of Nursing Practice

Theories play an essential role in organizing patient care. Theories refer to a proposed or followed belief, policy, or procedure that is the basis for action. Nursing theories are knowledge-based concepts that guide nurses' actions, influence nursing education and practice, and allow nurses to care for their patients.
Theories provide a perspective to assess patients' conditions and organize data and methods. They also assist in analyzing and interpreting information. They represent a...
17.3K
Equivalent Circuits for Practical Transformers01:28

Equivalent Circuits for Practical Transformers

The practical equivalent circuits of single-phase two-winding transformers exhibit significant deviations from their idealized versions due to the inherent properties of winding resistance and finite core permeability. These properties result in real and reactive power losses, affecting the transformer's performance. Understanding these deviations is crucial for designing more efficient transformers.
In a practical transformer, each winding exhibits resistance and leakage reactance. The...
1.4K
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.3K